Two Sigma Investments, LP Gamida Cell Ltd. Transaction History

Two Sigma Investments, LP

$40.3 Billion
Q1 2024

A detailed history of Two Sigma Investments, LP transactions in Gamida Cell Ltd. stock. As of the latest transaction made, Two Sigma Investments, LP holds 106,081 shares of GMDA stock, worth $3,182. This represents 0.0% of its overall portfolio holdings.

Number of Shares

106,081

Previous 124,226 14.61%

Holding current value

$3,182

Previous $50,000 92.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.04 - $0.46 $725 - $8,346	-18,145 Reduced 14.61%	106,081 $4,000
Q4 2023 Feb 14, 2024	BUY	$0.25 - $1.02 $27,781 - $113,348	111,126 Added 848.29%	124,226 $50,000
Q3 2023 Nov 14, 2023	SELL	$0.85 - $1.87 $14,053 - $30,916	-16,533 Reduced 55.79%	13,100 $13,000
Q2 2023 Aug 14, 2023	BUY	$0.73 - $2.37 $6,594 - $21,408	9,033 Added 43.85%	29,633 $57,000
Q1 2023 May 15, 2023	BUY	$0.68 - $1.71 $14,008 - $35,226	20,600 New	20,600 $16,000

Q1 2022 May 16, 2022	SELL	$2.22 - $4.47 $36,394 - $73,281	-16,394 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.2 - $4.46 $302,013 - $612,264	-137,279 Reduced 89.33%	16,394 $42,000
Q3 2021 Nov 15, 2021	BUY	$3.85 - $6.44 $350,681 - $586,593	91,086 Added 145.54%	153,673 $602,000
Q2 2021 Aug 16, 2021	BUY	$5.85 - $8.33 $366,133 - $521,349	62,587 New	62,587 $401,000
Q1 2021 May 17, 2021	SELL	$7.8 - $12.43 $191,911 - $305,827	-24,604 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$4.07 - $11.0 $120,842 - $326,601	-29,691 Reduced 54.68%	24,604 $206,000
Q3 2020 Nov 16, 2020	BUY	$3.93 - $4.59 $213,379 - $249,214	54,295 New	54,295 $225,000

Others Institutions Holding GMDA

# of Institutions

Shares Held

11.4M

Call Options Held

235K

Put Options Held

70.5K

View Full List

About Gamida Cell Ltd.

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

More about GMDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Account

Two Sigma Investments, LP Gamida Cell Ltd. Transaction History